StockWatch
·
Biotechnology: Pharmaceutical Preparations
Quarterly ResultMay 6, 2026, 04:13 PM

MannKind Q1 Net Loss $(16.6)M; Revenue +15.1%

AI Summary

MannKind reported a net loss of $(16.6) million for Q1 2026, a significant decline from a net income of $13.2 million in Q1 2025, despite a 15.1% increase in total revenues to $90.2 million. The shift to a net loss was primarily driven by a substantial increase in selling, general, and administrative expenses, which more than doubled year-over-year. Commercial product sales saw strong growth, while collaboration and services revenue decreased.

Key Highlights

  • Net loss of $(16.6) million in Q1 2026, compared to net income of $13.2 million in Q1 2025.
  • Total revenues increased 15.1% to $90.2 million for Q1 2026 from $78.4 million in Q1 2025.
  • Basic net loss per share was $(0.05) in Q1 2026, down from basic net income per share of $0.04 in Q1 2025.
  • Commercial product sales surged 78.7% to $33.9 million in Q1 2026 from $19.0 million in Q1 2025.
  • Royalties increased 9.1% to $32.7 million in Q1 2026 from $30.0 million in Q1 2025.
  • Selling, general and administrative expenses more than doubled to $54.1 million in Q1 2026 from $25.0 million in Q1 2025.
  • Net cash used in operating activities improved to $(5.4) million in Q1 2026 from $(6.4) million in Q1 2025.
  • Cash and cash equivalents decreased to $52.8 million as of March 31, 2026, from $74.9 million at Dec 31, 2025.